BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ideozu JE, Zhang X, McColley S, Levy H. Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. Genes (Basel) 2019;10:E180. [PMID: 30813620 DOI: 10.3390/genes10030180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Guan WJ, Hu PC, Martinez-Garcia MA. The transcriptomic landscape of diffuse radiological bronchiectasis. Eur Respir J 2023;61:2201733. [PMID: 36707228 DOI: 10.1183/13993003.01733-2022] [Reference Citation Analysis]
2 Grigoreva TA, Sagaidak AV, Novikova DS, Tribulovich VG. Implication of ABC transporters in non-proliferative diseases. European Journal of Pharmacology 2022;935:175327. [DOI: 10.1016/j.ejphar.2022.175327] [Reference Citation Analysis]
3 Hanssens LS, Duchateau J, Casimir GJ. CFTR Protein: Not Just a Chloride Channel? Cells 2021;10:2844. [PMID: 34831067 DOI: 10.3390/cells10112844] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
4 Hodos RA, Strub MD, Ramachandran S, Li L, McCray PB Jr, Dudley JT. Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue. Sci Rep 2020;10:20553. [PMID: 33239626 DOI: 10.1038/s41598-020-76347-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Amaral MD. How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics. Eur J Med Chem 2021;210:112989. [PMID: 33190956 DOI: 10.1016/j.ejmech.2020.112989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Mitri C, Xu Z, Bardin P, Corvol H, Touqui L, Tabary O. Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Front Pharmacol 2020;11:1096. [PMID: 32848733 DOI: 10.3389/fphar.2020.01096] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
7 Schupp JC, Khanal S, Gomez JL, Sauler M, Adams TS, Chupp GL, Yan X, Poli S, Montgomery RR, Rosas IO, Cruz CSD, Bruscia EM, Egan ME, Kaminski N, Britto CJ. Single Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.. [DOI: 10.1101/2020.03.06.20032292] [Reference Citation Analysis]
8 ElKhouly AM, Youness RA, Gad MZ. MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions. Noncoding RNA Res 2020;5:11-21. [PMID: 31993547 DOI: 10.1016/j.ncrna.2020.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
9 Ideozu JE, Zhang X, Rangaraj V, McColley S, Levy H. Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis. Sci Rep 2019;9:15483. [PMID: 31664087 DOI: 10.1038/s41598-019-51890-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
10 Chiarelli N, Ritelli M, Zoppi N, Colombi M. Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes. Genes (Basel) 2019;10:E609. [PMID: 31409039 DOI: 10.3390/genes10080609] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
11 Ideozu JE, Rangaraj V, Abdala-Valencia H, Zhang X, Kandpal M, Sala MA, Davuluri RV, Levy H. Transcriptional consequences of impaired immune cell responses induced by cystic fibrosis plasma characterized via dual RNA sequencing. BMC Med Genomics 2019;12:66. [PMID: 31118097 DOI: 10.1186/s12920-019-0529-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]